Ovid Therapeutics Inc
OVID
Get informed when a big investor buys or sells
+ FollowMarket Cap$299.38M
Close$
$-2.02
180.8% downside
Current Fair Value
180.8% downsideOvervalued by 180.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $299.38 Million |
|---|---|
| Enterprise Value | $206.77 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.24 |
| Beta | 0.18 |
| Outstanding Shares | 73,735,606 |
Return
| Return on Equity | -12.19% |
|---|---|
| Return on Assets | -10.71% |
| Return on Invested Capital | -22.64% |
Valuation & Multiples
| P/E Ratio | -6.93 |
|---|---|
| PEG | -10.5 |
| Price to Sales | - |
| Price to Book Ratio | 1.25 |
| Enterprise Value to Revenue | 29.03 |
| Enterprise Value to EBIT | -4.35 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$56,667
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$35,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.6257▲ 137.34% |
|---|---|
| Total Calls | 110,600▼ 10.01% |
| Total Puts | 179,800▲ 480.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 142.49%▲ 55.48% |
|---|---|
| Total Invested | $233.18M▲ 131.58% |
| Investors Holding | 109▲ 19.00% |
ESG Score
No data
About Ovid Therapeutics Inc
CEO: Jeremy Levin